Study details
Enrolling now
Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis
Yale University
NCT IDNCT06375811ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
297
Study length
about 2.5 years
Ages
18–40
Sex
Female only
Locations
5 sites in CO, CT, IL +2
What this study is about
This trial is testing whether taking a GnRH antagonist before IVF improves the chance of having a baby in women with endometriosis. The treatment involves taking Elagolix or a placebo, and comparing it to standard care (SOC) IVF.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo or SOC IVF
- 2.Take Elagolix 200 MG
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
elagolix
Drug routes
oral (Oral Tablet)
Body systems
Reproductive Health